Matched Ig sequences in single-cell sorted EBV-infected cell lines
| CLL ID . | IGHV . | IGHV mutation, % . | No. of cell lines sorted* . | Total no. of sequences . | No. of matched IGHV genes† . | Matched IGHV genes, % . | CD5+ CD19+ cells in PBMCs, % . |
|---|---|---|---|---|---|---|---|
| CLL246‡ | 1-69 | 0.3 | 3 | 32 | 32 | 100 | ND |
| CLL493‡ | 1-69 | 0 | 1 | 7 | 7 | 100 | 99.8 |
| CLL526‡ | 1-69 | 0 | 2 | 5 | 4 | 80 | ND |
| CLL675 | 3-23 | 0 | 1 | 1 | 0 | 0 | 99.8 |
| CLL698 | 1-69 | 0 | 5 | 17 | 2 | 11.8 | ND |
| CLL701 | 1-69 | 0 | 2 | 17 | 8 | 47.1 | 75.7 |
| CLL753 | 3-74 | 0 | 2 | 12 | 7 | 58.3 | 95.5 |
| CLL815‡ | 1-69 | 0 | 1 | 9 | 9 | 100 | 99.5 |
| CLL861‡ | 1-69 | 0 | 1 | 13 | 13 | 100 | 99.6 |
| CLL1073 | 1-69 | 0 | 2 | 14 | 0 | 0 | 94.7 |
| CLL1121‡ | 3-11 | 0 | 3 | 18 | 17 | 94.4 | 99.5 |
| CLL1153‡ | 1-69 | 0 | 2 | 11 | 10 | 90.9 | 80.7 |
| CLL1191 | 3-23 | 0 | 1 | 16 | 1 | 6.3 | 99.9 |
| CLL1288 | 3-11 | 0 | 1 | 10 | 0 | 0 | ND |
| CLL1324‡ | 1-69 | 0 | 4 | 18 | 16 | 88.9 | 98.7 |
| CLL1011 | 1-69 | 3.8 | 1 | 2 | 0 | 0 | 99.4 |
| CLL1080 | 3-09 | 2.8 | 1 | 17 | 0 | 0 | 99.4 |
| CLL1193‡ | 3-13 | 6.3 | 1 | 9 | 9 | 100 | ND |
| CLL1200 | 2-05 | 3.8 | 2 | 25 | 0 | 0 | 96.6 |
| CLL1223 | 2-05 | 6.2 | 1 | 9 | 0 | 0 | 97.1 |
| CLL1296 | 3-07 | 7.6 | 1 | 3 | 0 | 0 | 99.6 |
| CLL ID . | IGHV . | IGHV mutation, % . | No. of cell lines sorted* . | Total no. of sequences . | No. of matched IGHV genes† . | Matched IGHV genes, % . | CD5+ CD19+ cells in PBMCs, % . |
|---|---|---|---|---|---|---|---|
| CLL246‡ | 1-69 | 0.3 | 3 | 32 | 32 | 100 | ND |
| CLL493‡ | 1-69 | 0 | 1 | 7 | 7 | 100 | 99.8 |
| CLL526‡ | 1-69 | 0 | 2 | 5 | 4 | 80 | ND |
| CLL675 | 3-23 | 0 | 1 | 1 | 0 | 0 | 99.8 |
| CLL698 | 1-69 | 0 | 5 | 17 | 2 | 11.8 | ND |
| CLL701 | 1-69 | 0 | 2 | 17 | 8 | 47.1 | 75.7 |
| CLL753 | 3-74 | 0 | 2 | 12 | 7 | 58.3 | 95.5 |
| CLL815‡ | 1-69 | 0 | 1 | 9 | 9 | 100 | 99.5 |
| CLL861‡ | 1-69 | 0 | 1 | 13 | 13 | 100 | 99.6 |
| CLL1073 | 1-69 | 0 | 2 | 14 | 0 | 0 | 94.7 |
| CLL1121‡ | 3-11 | 0 | 3 | 18 | 17 | 94.4 | 99.5 |
| CLL1153‡ | 1-69 | 0 | 2 | 11 | 10 | 90.9 | 80.7 |
| CLL1191 | 3-23 | 0 | 1 | 16 | 1 | 6.3 | 99.9 |
| CLL1288 | 3-11 | 0 | 1 | 10 | 0 | 0 | ND |
| CLL1324‡ | 1-69 | 0 | 4 | 18 | 16 | 88.9 | 98.7 |
| CLL1011 | 1-69 | 3.8 | 1 | 2 | 0 | 0 | 99.4 |
| CLL1080 | 3-09 | 2.8 | 1 | 17 | 0 | 0 | 99.4 |
| CLL1193‡ | 3-13 | 6.3 | 1 | 9 | 9 | 100 | ND |
| CLL1200 | 2-05 | 3.8 | 2 | 25 | 0 | 0 | 96.6 |
| CLL1223 | 2-05 | 6.2 | 1 | 9 | 0 | 0 | 97.1 |
| CLL1296 | 3-07 | 7.6 | 1 | 3 | 0 | 0 | 99.6 |
ND indicates not determined.
After 5-6 weeks of continuous culture, selected IgM-producing wells from 21 EBV-infected B-CLL samples were sorted as single cells for Ig sequencing.
The cells with matched Ig sequences had IGHV sequences that matched those of the previously identified B-CLL IgM sequences from the same patient samples.30
Each PBMC sample produced at least 1 cell line with all matched IGHV sequences.